Advertisement
Letter to the Editor| Volume 147, P60-62, April 2021

Download started.

Ok

Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E–mutated colorectal cancer

  • Romain Stammler
    Affiliations
    Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France
    Search for articles by this author
  • Claire Gallois
    Affiliations
    Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France
    Search for articles by this author
  • Julien Taieb
    Affiliations
    Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France
    Search for articles by this author
  • Jean-Paul Duong
    Affiliations
    Department of Pathology, Hôpital Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France
    Search for articles by this author
  • Alexandre Karras
    Affiliations
    Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France
    Search for articles by this author
  • Eric Thervet
    Affiliations
    Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France
    Search for articles by this author
  • Hélène Lazareth
    Correspondence
    Corresponding author: Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris Department of Nephrology, 20 rue Leblanc, 75015 Paris, France. Fax: +0033 1 56 09 33 62.
    Affiliations
    Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France
    Search for articles by this author
Published:February 19, 2021DOI:https://doi.org/10.1016/j.ejca.2021.01.024
Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E–mutated colorectal cancer
Previous ArticleAcute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma
Next ArticlePrevention of healthcare-associated respiratory-viral infections amongst oncology inpatients: Infection prevention outcomes during coronavirus disease-2019 pandemic
      Approximately, 10% of metastatic colorectal cancers display BRAF V600E mutation. Although originally associated with poor outcomes, new targeted therapies have improved their prognosis. The phase III multicenter randomised BEACON trial showed that, second-line triple therapy combining binimetinib, encorafenib and cetuximab improved response rate, as well as progression-free and overall survival among these patients [
      • Kopetz S.
      • Grothey A.
      • Yaeger R.
      • Van Cutsem E.
      • Desai J.
      • Yoshino T.
      • et al.
      Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer.
      N Engl J Med. 2019 Oct 24; 381: 1632-1643
      ]. No nephrotoxicity has yet been reported with the association of these three drugs.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Kopetz S.
        • Grothey A.
        • Yaeger R.
        • Van Cutsem E.
        • Desai J.
        • Yoshino T.
        • et al.
        Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer.
        N Engl J Med. 2019 Oct 24; 381: 1632-1643
        View in Article
        • Heinzerling L.
        • Eigentler T.K.
        • Fluck M.
        • Hassel J.C.
        • Heller-Schenck D.
        • Leipe J.
        • et al.
        Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.
        ESMO Open. 2019 May; 4e000491
        View in Article
        • Maanaoui M.
        • Saint-Jacques C.
        • Gnemmi V.
        • Frimat M.
        • Lionet A.
        • Hazzan M.
        • et al.
        Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: a case report.
        Medicine (Baltim). 2017 Jun; 96e7196
        View in Article
        • Hurabielle C.
        • Pillebout E.
        • Stehlé T.
        • Pagès C.
        • Roux J.
        • Schneider P.
        • et al.
        Mechanisms underpinning increased plasma creatinine levels in patients receiving vemurafenib for advanced melanoma.
        PloS One. 2016 Mar 1; 11e0149873
        View in Article
        • Rayego-Mateos S.
        • Rodrigues-Diez R.
        • Morgado-Pascual J.L.
        • Valentijn F.
        • Valdivielso J.M.
        • Goldschmeding R.
        • et al.
        Role of Epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage.
        Mediat Inflamm. 2018 Dec 23; (2018): 1-22
        View in Article

      Article info

      Publication history

      Published online: February 19, 2021
      Accepted: January 16, 2021
      Received in revised form: January 5, 2021
      Received: October 9, 2020

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2021.01.024

      Copyright

      © 2021 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX